Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
暂无分享,去创建一个
Thomas Steckler | Athina Markou | M. Geyer | C. Chiamulera | T. Steckler | M. Tricklebank | A. Markou | Mark A Geyer | Mark Tricklebank | Christian Chiamulera
[1] David F. Horrobin,et al. Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.
[2] M. Brodie. Do we need any more new antiepileptic drugs? , 2001, Epilepsy Research.
[3] A. Grace,et al. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. , 2005, Schizophrenia bulletin.
[4] R. Freeman,et al. Neurometabolic coupling in cerebral cortex reflects synaptic more than spiking activity , 2007, Nature Neuroscience.
[5] T. Insel,et al. Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective , 2003, Psychopharmacology.
[6] Y. Lecrubier. Refinement of diagnosis and disease classification in psychiatry , 2008, European Archives of Psychiatry and Clinical Neuroscience.
[7] N. Schork,et al. Advances in endophenotyping schizophrenia , 2008, World psychiatry : official journal of the World Psychiatric Association.
[8] David Roblin,et al. Translational research in the pharmaceutical industry: from bench to bedside. , 2006, Drug discovery today.
[9] Bruce H. Littman,et al. The ultimate model organism: progress in experimental medicine , 2005, Nature Reviews Drug Discovery.
[10] E K Perry,et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.
[11] M. Millan,et al. The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. , 2003, European journal of pharmacology.
[12] Nick C Fox,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.
[13] J. Callicott,et al. Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer? , 2008, Molecular Psychiatry.
[14] T. Steckler,et al. Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update. , 2006, CNS & neurological disorders drug targets.
[15] Esther F. Schmid,et al. Keynote review: Is declining innovation in the pharmaceutical industry a myth? , 2005, Drug discovery today.
[16] David Gonzales,et al. Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial , 2006 .
[17] J. Shields,et al. Genetic Theorizing and Schizophrenia , 1973, British Journal of Psychiatry.
[18] G. Dawson,et al. Use of the elevated plus maze in the search for novel anxiolytic agents. , 1995, Trends in pharmacological sciences.
[19] M. Geyer. The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps? , 2006, Neurotoxicity Research.
[20] M. Geyer. 33 THE ROLE OF PRECLINICAL MODELS IN THE DEVELOPMENT OF PSYCHOTROPIC DRUGS , 2002 .
[21] D. DeMets,et al. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. , 2001, Controlled clinical trials.
[22] A. Harrison,et al. Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors. , 2001, The Journal of pharmacology and experimental therapeutics.
[23] J. Schildkraut,et al. The catecholamine hypothesis of affective disorders. A review of supporting evidence. , 1967, International journal of psychiatry.
[24] J. Crawley,et al. Behavioral Phenotyping Strategies for Mutant Mice , 2008, Neuron.
[25] B. Imbimbo. Toxicity of β‐amyloid vaccination in patients with Alzheimer's disease , 2002 .
[26] P P Humphrey,et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.
[27] M. Sarter. Preclinical research into cognition enhancers. , 2006, Trends in pharmacological sciences.
[28] Dennis S. Charney,et al. Neuropsychopharmacology : The Fifth Generation of Progress , 2002 .
[29] T. Enomoto,et al. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. , 2007, Methods and findings in experimental and clinical pharmacology.
[30] S. Mandel,et al. Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties. , 2007, Current Alzheimer research.
[31] S. Mineka,et al. Animal Models of Psychopathology , 1991 .
[32] M. Pangalos,et al. Drug development for CNS disorders: strategies for balancing risk and reducing attrition , 2007, Nature Reviews Drug Discovery.
[33] S. Arneric,et al. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. , 2007, Biochemical pharmacology.
[34] D. Schoepp,et al. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine , 2000, Psychopharmacology.
[35] Jason Eriksen,et al. A decade of modeling Alzheimer's disease in transgenic mice. , 2006, Trends in genetics : TIG.
[36] Anil K Malhotra,et al. Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.
[37] A. P. Carobrez,et al. Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on , 2005, Neuroscience & Biobehavioral Reviews.
[38] K. Lundstrom,et al. Structural genomics and drug discovery , 2007, Journal of cellular and molecular medicine.
[39] S. Hyman,et al. Medicine. What are the right targets for psychopharmacology? , 2003, Science.
[40] J. Streffer,et al. Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.
[41] A. Markou,et al. Animal models and treatments for addiction and depression co-morbidity , 2009, Neurotoxicity Research.
[42] R. Porsolt,et al. Behavioural despair in rats: a new model sensitive to antidepressant treatments. , 1978, European journal of pharmacology.
[43] Innovation OR Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .
[44] D. Wong,et al. The Discovery of Fluoxetine Hydrochloride (Prozac) , 2005, Nature Reviews Drug Discovery.
[45] D. Roblin,et al. Translational research in the pharmaceutical industry: from theory to reality. , 2007, Drug discovery today.
[46] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[47] J Drews,et al. The role of innovation in drug development. , 1997, Nature biotechnology.
[48] P. Davies,et al. SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.
[49] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[50] Stephen M Stahl,et al. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. , 2007, Trends in pharmacological sciences.
[51] Martin P. Paulus,et al. A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor , 2007, Neuroscience & Biobehavioral Reviews.
[52] Josemir W Sander,et al. The excitatory amino acid antagonist d-CPP-ene (SDZ EAA-494) in patients with epilepsy , 1993, Epilepsy Research.
[53] Craig A. Grimes,et al. Encyclopedia of Sensors , 2006 .
[54] B. Poland,et al. Combining drug-disease and economic modelling to inform drug development decisions. , 2001, Drug discovery today.
[55] R. Mcarthur,et al. PREFACE: What Do You Mean by “Translational Research”? An Enquiry Through Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders , 2008 .
[56] I. Kola,et al. The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.
[57] P. Kenny,et al. Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories , 2009, Neurotoxicity Research.
[58] M. Geyer,et al. New approaches to measurement and treatment research to improve cognition in schizophrenia. , 2005, Schizophrenia bulletin.
[59] I. Gottesman,et al. Psychiatric endophenotypes and the development of valid animal models , 2006, Genes, brain, and behavior.
[60] D. Premack. Human and animal cognition: Continuity and discontinuity , 2007, Proceedings of the National Academy of Sciences.
[61] S. Handley,et al. Serotonin mechanisms in animal models of anxiety. , 1993, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[62] D. Overstreet,et al. Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories , 1991, Synapse.
[63] F. Bloom,et al. Psychopharmacology: The Fourth Generation of Progress , 1995 .
[64] S. Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.
[65] A. Halberstadt. The phencyclidine-glutamate model of schizophrenia. , 1995, Clinical neuropharmacology.
[66] W. Fenton,et al. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia , 2004, Schizophrenia Research.
[67] G. Andrews,et al. Classification of Anxiety and Depressive disorders: problems and solutions , 2008, Depression and anxiety.
[68] P. Williams. The role of pharmacological profiling in safety assessment. , 1990, Regulatory toxicology and pharmacology : RTP.
[69] B. Imbimbo. Toxicity of beta-amyloid vaccination in patients with Alzheimer's disease. , 2002, Annals of neurology.
[70] N. Rigotti,et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. , 2006, JAMA.
[71] D. Javitt,et al. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. , 1987, The Hillside journal of clinical psychiatry.
[72] G. Rosenbaum,et al. Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.
[73] T. Robbins,et al. Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans , 2006, Science.
[74] J. Glowinski,et al. EFFECT OF DRUGS ON THE UPTAKE, RELEASE, AND METABOLISM OF H3-NOREPINEPHRINE IN THE RAT BRAIN. , 1965, The Journal of pharmacology and experimental therapeutics.
[75] T. Robbins,et al. Functions of frontostriatal systems in cognition: Comparative neuropsychopharmacological studies in rats, monkeys and humans , 2006, Biological Psychology.
[76] S. File,et al. Factors controlling measures of anxiety and responses to novelty in the mouse , 2001, Behavioural Brain Research.
[77] A. Mortimer. Cognitive Function in Schizophrenia— Do Neuroleptics Make a Difference? , 1997, Pharmacology Biochemistry and Behavior.
[78] D R Medoff,et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.
[79] J. Lieberman,et al. Methylphenidate and neuroleptic effects on oral word production in schizophrenia , 1992 .
[80] Nash N. Boutros,et al. P50 sensory gating ratios in schizophrenics and controls: A review and data analysis , 2008, Psychiatry Research.
[81] M. Low,et al. Dopamine D4 Receptor-Knock-Out Mice Exhibit Reduced Exploration of Novel Stimuli , 1999, The Journal of Neuroscience.
[82] S. Iversen,et al. Dopamine: 50 years in perspective , 2007, Trends in Neurosciences.
[83] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[84] T. Robbins,et al. Inhibitory control in rats performing a stop-signal reaction-time task: effects of lesions of the medial striatum and d-amphetamine. , 2003, Behavioral neuroscience.
[85] P. Willner. Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMS , 2005, Neuropsychobiology.
[86] H. Kraemer,et al. Biomarkers in psychiatry: methodological issues. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[87] J. Tallman. Neuropsychopharmacology at the New Millennium: New Industry Directions , 1999, Neuropsychopharmacology.
[88] T. Robbins,et al. Early experience as a determinant of adult behavioural responses to reward: the effects of repeated maternal separation in the rat , 2003, Neuroscience & Biobehavioral Reviews.
[89] M. Geyer. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? , 2006, Dialogues in clinical neuroscience.
[90] Jason Gong,et al. Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .
[91] F. Sams-Dodd. Target-based drug discovery: is something wrong? , 2005, Drug discovery today.
[92] M. Picciotto,et al. Neuronal Systems Underlying Behaviors Related to Nicotine Addiction: Neural Circuits and Molecular Genetics , 2002, The Journal of Neuroscience.
[93] T. Feuerstein. Presynaptic receptors for dopamine, histamine, and serotonin. , 2008, Handbook of experimental pharmacology.
[94] Peter Imming,et al. Drugs, their targets and the nature and number of drug targets , 2007, Nature Reviews Drug Discovery.
[95] D. Balfour,et al. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell , 2007, The European journal of neuroscience.
[96] N. Bond. Animal models in psychopathology , 1984 .
[97] J. Crawley. Exploratory behavior models of anxiety in mice , 1985, Neuroscience & Biobehavioral Reviews.
[98] I. Liberzon,et al. Summary of a National Institute of Mental Health workshop: developing animal models of anxiety disorders , 2001, Psychopharmacology.
[99] D. Marazziti,et al. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? , 2002, Psychopharmacology.
[100] R. Hargreaves,et al. Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.
[101] T. Robbins,et al. Similar Effects of the Selective Noradrenaline Reuptake Inhibitor Atomoxetine on Three Distinct Forms of Impulsivity in the Rat , 2008, Neuropsychopharmacology.
[102] M. Lindsay. Target discovery , 2003, Nature Reviews Drug Discovery.
[103] A. Coppen. The Biochemistry of Affective Disorders , 1967, British Journal of Psychiatry.
[104] D. Drachman,et al. Memory and cognitive function in man , 1977, Neurology.
[105] L. Iversen,et al. Neurotransmitter transporters and their impact on the development of psychopharmacology , 2006, British journal of pharmacology.
[106] Berry M Spruijt,et al. Advanced behavioural screening: automated home cage ethology. , 2006, Drug discovery today. Technologies.
[107] C. Morgan,et al. Acute and chronic effects of ketamine upon human memory: a review , 2006, Psychopharmacology.
[108] R. Hurst,et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. , 2007, Neuropharmacology.
[109] S. B. Caine,et al. Animal models of drug craving , 2005, Psychopharmacology.
[110] R. Rodgers,et al. Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze , 1995, Pharmacology Biochemistry and Behavior.
[111] T. Blackburn,et al. The medical benefit of 5-HT research , 2002, Pharmacology Biochemistry and Behavior.
[112] Athina Markou,et al. Assessing antidepressant activity in rodents: recent developments and future needs. , 2002, Trends in pharmacological sciences.
[113] R. Horowski,et al. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports , 1985 .
[114] W. Bunney,et al. Norepinephrine in depressive reactions. A review. , 1965, Archives of general psychiatry.
[115] L. Cronbach,et al. Construct validity in psychological tests. , 1955, Psychological bulletin.
[116] Opportunities and Challenges of Psychiatric Drug Discovery: Roles for Scientists in Academic, Industry, and Government Settings , 2008, Neuropsychopharmacology.
[117] A. Cools,et al. Animal models for the negative symptoms of schizophrenia , 2000, Behavioural pharmacology.
[118] P. D. De Deyn,et al. Drug discovery in dementia: the role of rodent models. , 2006, Nature reviews. Drug discovery.
[119] W. Spooren,et al. Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety , 2008, Psychopharmacology.
[120] G. Koob,et al. Neurobiological Similarities in Depression and Drug Dependence: A Self-Medication Hypothesis , 1998, Neuropsychopharmacology.
[121] T. Jay,et al. A pathophysiological paradigm for the therapy of psychiatric disease , 2005, Nature Reviews Drug Discovery.
[122] N. Varney,et al. Psychopharmacology: The Fourth Generation of Progress. , 1996 .
[123] Michael F. Green,et al. Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative , 2008, Biological Psychiatry.
[124] J. Götz,et al. Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.
[125] E. Jacobsen. The early history of psychotherapeutic drugs , 2004, Psychopharmacology.
[126] A. Harrison,et al. Paroxetine combined with a 5-HT1A receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats , 2005, Psychopharmacology.
[127] M. M. Moraes. Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze , 1999 .
[128] M. Tricklebank. The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems , 1995, Behavioural Brain Research.
[129] E. Bullmore,et al. Acute Ketamine Administration Alters the Brain Responses to Executive Demands in a Verbal Working Memory Task: an fMRI Study , 2004, Neuropsychopharmacology.
[130] Solomon Nwaka,et al. Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships , 2003, Nature Reviews Drug Discovery.
[131] Allan Collins,et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies , 1997, Psychopharmacology.
[132] M. Brandão,et al. Acute and Chronic Effects of Gepirone and Fluoxetine in Rats Tested in the Elevated Plus-maze An Ethological Analysis , 2000, Pharmacology Biochemistry and Behavior.
[133] C. Gorodetzky,et al. Involving the pharmaceutical and biotech communities in medication development for substance abuse. , 2005, Pharmacology & therapeutics.
[134] C. Carter,et al. Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. , 2007, Schizophrenia bulletin.
[135] Robert S. Astur,et al. Factors affecting the hippocampal BOLD response during spatial memory , 2008, Behavioural Brain Research.
[136] B. Gallhofer,et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs , 1996, European Neuropsychopharmacology.
[137] M. Stein,et al. Developing Novel Anxiolytics: Improving Preclinical Detection and Clinical Assessment , 2008 .
[138] J. Gogos,et al. Modeling Madness in Mice: One Piece at a Time , 2006, Neuron.
[139] S. Rennard,et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. , 2006, JAMA.
[140] H. Manji,et al. Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder , 2006, Biological Psychiatry.
[141] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[142] D. Westaway,et al. New developments in animal models of Alzheimer’s disease , 2001, Current neurology and neuroscience reports.
[143] A. Green. Neuropharmacology of 5-hydroxytryptamine. , 2006, British journal of pharmacology.
[144] Michael F. Green,et al. Identification of separable cognitive factors in schizophrenia , 2004, Schizophrenia Research.
[145] R. Lister. The use of a plus-maze to measure anxiety in the mouse , 2004, Psychopharmacology.
[146] A. Markou,et al. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats , 2007, Psychopharmacology.
[147] A. Markou,et al. Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats , 2003, Synapse.
[148] R. Freedman,et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.
[149] D. S. Parker,et al. A collaborative knowledge base for cognitive phenomics , 2008, Molecular Psychiatry.
[150] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[151] C. Chiamulera,et al. Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia , 2007 .
[152] D. Javitt,et al. Neurophysiological biomarkers for drug development in schizophrenia , 2008, Nature Reviews Drug Discovery.
[153] M. Geyer,et al. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity , 2002, Neuropharmacology.
[154] G. Velo. Erice statement on drug innovation. , 2008, British journal of clinical pharmacology.
[155] M. Geyer,et al. Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects , 2004, Psychopharmacology.
[156] A. S. Freeman,et al. Relationship between the development of behavioral tolerance and the biodisposition of phencyclidine in mice , 1984, Pharmacology Biochemistry and Behavior.
[157] D. Skovronsky,et al. Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[158] A. Harrison,et al. Fluoxetine Combined with a Serotonin-1A Receptor Antagonist Reversed Reward Deficits Observed during Nicotine and Amphetamine Withdrawal in Rats , 2001, Neuropsychopharmacology.
[159] A. Coppen,et al. Serotonin and its place in the pathogenesis of depression. , 1988, The Journal of clinical psychiatry.
[160] Herbert Weingartner,et al. NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers , 1996, Neuropsychopharmacology.
[161] M. Kurt,et al. The Effects of Sertraline and Fluoxetine on Anxiety in the Elevated Plus-Maze Test , 2000, Journal of basic and clinical physiology and pharmacology.
[162] A. Holmes. Targeted gene mutation approaches to the study of anxiety-like behavior in mice , 2001, Neuroscience & Biobehavioral Reviews.
[163] C. Hart,et al. Finding the target after screening the phenotype. , 2005, Drug discovery today.